Evonile Pharma Ltd has launched a rights issue of 10.28 million equity shares priced at Rs 860 per share to raise Rs 8,847.54 million. The capital will primarily reduce company debt, with payments split into two tranches. Existing shareholders as of November 11, 2026, are eligible to participate.
Evonile Pharma Announces Rs 885 Crore Rights Issue
Issue Price: Rs 860 per share | Objective: Rs 8,000 million allocated for debt repayment.
Reader Takeaway: Rights issue strengthens balance sheet via debt reduction, though investors must monitor ongoing tax and regulatory legal risks.
What just happened
Evonile Pharma Ltd has officially announced a rights issue of up to 10,287,832 equity shares to raise approximately Rs 8,847.54 million. The issue is priced at Rs 860 per share and follows a 5:12 ratio. Shareholders on the record date of November 11, 2026, are eligible to participate in this offering. The payment structure is split into two parts: 75% (Rs 645) due on application and 25% (Rs 215) due upon the first and final call.
Why this matters
The primary driver for this capital raise is debt reduction. The company intends to use roughly Rs 8,000 million to repay or pre-pay outstanding borrowings, accrued interest, and penalties. By clearing this debt, Evonile Pharma aims to improve its leverage position following its recent change in control.
The backstory
Formerly known as Novartis India Limited, the company underwent a major transition in July 2026 when WaveRise Investments Limited and ChrysCapital Fund X assumed promoter control. The company functions under an asset-light model, relying exclusively on third-party contract manufacturers for its product portfolio.
Risks to watch
Investors should be aware of several operational and legal challenges. The company is currently involved in outstanding legal proceedings, including criminal and tax-related matters. Notably, it has earmarked contingent liabilities of Rs 416.2 million related to Drug Price Control Order (DPCO) cases. Additionally, as an asset-light entity, the firm is entirely dependent on third-party manufacturers, posing potential supply chain risks if integration or operational continuity is disrupted during this ownership transition.
What to track next
- Issue Opening Date: November 19, 2026
- Issue Closing Date: December 3, 2026
- Allotment Date: December 4, 2026
- Listing Date: December 9, 2026